Viatris (HAM:VIA) Short-Term Debt: €1,667 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HAM:VIA Viatris Inc HAM:VIA
60 GF Score
Price €15.11
GF Value €9.46
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Viatris Short-Term Debt?

Viatris HAM:VIA +0.04% 60 Short-Term Debt is €1,667 Mil as of Mar. 2026. GuruFocus rates HAM:VIA with a GF Score™ of 60/100 and a GF Value™ of €9.46 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Viatris's Short-Term Debt for the quarter that ended in Mar. 2026 was €1,667 Mil.

Viatris's quarterly Short-Term Debt declined from Sep. 2025 (€1,657 Mil) to Dec. 2025 (€1,648 Mil) but then increased from Dec. 2025 (€1,648 Mil) to Mar. 2026 (€1,667 Mil).

Viatris's annual Short-Term Debt declined from Dec. 2023 (€1,774 Mil) to Dec. 2024 (€1 Mil) but then increased from Dec. 2024 (€1 Mil) to Dec. 2025 (€1,648 Mil).

Viatris Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Viatris Short-Term Debt Related Terms

Viatris Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Viatris's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viatris Short-Term Debt Chart

Viatris Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,967.67 1,180.47 1,774.12 0.57 1,648.14

Viatris Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.65 1,450.58 1,656.54 1,648.14 1,667.37
HAM:VIA
60GF Score
Viatris Inc HAM:VIA
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of €1,667 Mil mean?
Viatris (HAM:VIA) has a Short-Term Debt of €1,667 Mil as of Mar. 2026.
Is Viatris' Short-Term Debt too high?
Viatris' current Short-Term Debt is €1,667 Mil. Overall, Viatris has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Viatris' Short-Term Debt compare to NBIX and UTHR?
Viatris' Short-Term Debt of €1,667 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Drug Manufacturers company?
A good Short-Term Debt depends on the Drug Manufacturers industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Viatris's current Short-Term Debt is €1,667 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viatris stock overvalued right now?
Based on GuruFocus' analysis, Viatris (HAM:VIA) is currently considered Significantly Overvalued. The stock's GF Value™ is €9.46, compared to a current price of €15.11 — trading 59.7% above its estimated fair value. The current Short-Term Debt is €1,667 Mil. Viatris' overall GF Score™ is 60/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Viatris (HAM:VIA), the current Short-Term Debt is €1,667 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Viatris (HAM:VIA) Overvalued in 2026?

Based on GuruFocus' analysis, Viatris stock appears to be overvalued. The current stock price of €15.11 is trading 59.7% above its estimated GF Value™ of €9.46. GuruFocus considers Viatris to be Significantly Overvalued.

Key valuation signals for HAM:VIA:

  • Short-Term Debt: €1,667 Mil
  • GF Value™: €9.46 vs. price of €15.11 (59.7% above fair value)
  • GF Score™: 60/100 with 8 warning signs

No single metric tells the full story. See the HAM:VIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Viatris Business Description

Address 1000 Mylan Boulevard, Canonsburg, PA, USA, 15317
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
60GF Score

Get the complete analysis for HAM:VIA

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€15.11
Price
€9.46
GF Value